NCT01465828View on ClinicalTrials.gov

Therapy With High Clopidogrel Dose or Prasugrel Standard Dose Reduces the Platelet Reactivity in Patients With Genotype Variation RESET GENE Trial

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Acute Coronary Syndrome

Interventions

DRUG

Clopidogrel

Patient will be randomized to this intervention will receive in the first time the high clopidogrel dose and after 14 days we will change their therapy with standard dose of prasugrel (crossover).

DRUG

prasugrel

Patient will be randomized to this intervention will receive in the first time the standard dose of prasugrel and after 14 days we will change their therapy with high dose of clopidogrel (crossover).

Trial Locations (2)

00161

Dept.of Cardiovascular Sciences,Policlinico Umberto I, Roma

00155

Dept.of Cardiovascular Sciences,Policlinico Umberto I, Rome

All Listed Sponsors

lead

Gennaro Sardella

OTHER

NCT01465828 - Therapy With High Clopidogrel Dose or Prasugrel Standard Dose Reduces the Platelet Reactivity in Patients With Genotype Variation RESET GENE Trial | Biotech Hunter | Biotech Hunter